Nope, after Nov. 7th will be initiation of a new 2-73 trial for an orphan indication, before year's end (according to the company). Also, possible epilepsy phase 2 trial initiation. Also partnership talks, even buyout speculation. All soon after Nov 7th.
The Part B final results are huge. This compound will be used long term and the Part B dosing will be a therapeutic regimen (daily). A year of extended application under that protocol will suss out an even more accurate signal of efficacy.